We are phenofAST,

and we are redefining the timeline of life-saving antibiotics with precise
AST results available in just 4 hours. We are here to change the narrative,
to transform lives, and to revolutionize the health sector. Join us in this
life-changing mission. Let us together redefine the health sector timeline
and save more lives. Because time counts.

img
Challenge Problem About Us Solution Market Ask Time Counts Roadmap img 00:30
Problem

People are still dyeing
from treatable diseases.

It takes up to 5 days for hospital lab to test and find which
antibiotic will kills the bacteria.

50% of patients receive wrong antibiotic treatment for their infection.

Every 10 min, someone dies due to antibiotic
resistant bacteria infection.

img
Challenge Problem About Us Solution Market Ask Time Counts Roadmap img 01:00
Challenge

To arm doctors with the
right tools to act swiftly and
accurately, thereby saving
more lives.

img
Challenge Problem About Us Solution Market Ask Time Counts Roadmap img 01:30
Solution

PhenofAST AST analyser physics-based technology
provides AST results in just 4 hours.

Plate culturing Plate culturing Bacteria ID BacteriaID Doctor’s Report STANDARDLAB WORK FASTERRESULTS 24H 36H 48H 60H Standard antibioticsusceptibility testing (AST) Blood culturing Blood culturing Patient’s sample 4H 12H Plate culturing Plate culturing Bacteria ID BacteriaID Doctor’s Report STANDARD LAB WORK FASTER RESULTS 24H 36H 48H 60H Standard antibioticsusceptibilitytesting (AST) Blood culturing Blood culturing Patient’ssample 4H 12H
img
Challenge Problem About Us Solution Market Ask Time Counts Roadmap img 02:00
-$2 0% 2% 4% 6% 8% 10% 12% Market share $ Millions $23 $48 $73 $98 $123 $148 $173 $198 $223 $248 $273 Market share Gross revenues($M) Net revenues ($M) Revenues forecast TAM SAM SOM $36 billion $2.5 billion $750 million 30% -$2 0% 2% 4% 6% 8% 10% 12% Market share $ Millions $23 $48 $73 $98 $123 $148 $173 $198 $223 $248 $273 Market share Gross revenues($M) Net revenues ($M) Revenues forecast TAM SAM SOM $36 billion $2.5 billion $750 million 30%
Challenge Problem About Us Solution Market Ask Time Counts Roadmap img 02:30

ROADMAP 2nd-gen Prototype Manufacturing 3rd-gen PrototypeManufacturing 4th-gen PrototypeManufacturing Clinical Validation FDA Approvals International Clinical Pivot Studies International Clinical Trials 6m 12m 18m 28m 34m 40m 46m Design Freeze FDA’s 510(k) Manufacturing & Marketing Partnership PHASE 1 PHASE 2 PHASE 3 ROADMAP 2nd-gen Prototype Manufacturing 3rd-gen PrototypeManufacturing 4th-gen PrototypeManufacturing Clinical Validation Israel FDA Approvals International Clinical Pivot Studies International Clinical Trials 6m 12m 18m 28m 34m 40m 46m Design Freeze FDA’s 510(k) Manufacturing & Marketing Partnership PHASE 1 PHASE 2 PHASE 3
Challenge Problem About Us Solution Market Ask Time Counts Roadmap img 03:00
Ask

$2 million for the production of
a 2nd-gen prototype + clinical trials
in Israel, in order to achieve the
same or better result than 95%, in
agreement with the Golden
Standard.

img
Challenge Problem About Us Solution Market Ask Time Counts Roadmap img 03:30

TIME COUNTS

Let’s make our world healthier and safer.

Challenge Problem About Us Solution Market Ask Time Counts Roadmap 04:00